Gen Z’s Health Signal, Lilly’s $2.9B Bet, China PE Reawakens

Good morning, ! Healthcare investors have plenty to watch. Gen Z’s widening stress gap is creating a new demand signal, Eli Lilly is making a $2.9B bet on next-generation immunology, and healthcare PE activity in Greater China is finally showing signs of life.

Plus, GLP-1 exposure is driving another potential €3B exit, while Big Pharma keeps shopping for innovation beyond its own labs.

Know someone who would love this? Pass it along—they’ll thank you later! Here’s the link.

Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.

MICROSURVEY

HEADLINE OF THE WEEK

Gen Z’s Stress Is Becoming a Healthcare Demand Signal

Gen Z reports higher stress than millennials across nearly every category surveyed. The biggest pressure is long-term financial security, cited by 48% of Gen Z versus 45% of millennials, followed closely by family health and welfare at 46% versus 45%.

The more important signal is where the generational gap widens. 41% of Gen Z say family or personal relationships contribute to anxiety or stress, compared with 36% of millennials. Mental health concerns show the largest gap, 39% versus 33%. Physical health follows at 38% versus 35%. Only job-related stress is equal, at 35%.

Why it matters: Gen Z’s anxiety is not concentrated around employment. It spans financial, relational, mental, and physical wellbeing. For healthcare operators, employers, and investors, that points toward demand for more integrated behavioral health and wellness offerings rather than narrowly defined workplace benefits.

Bottom line: Gen Z’s stress profile is broader than millennials’, making mental health part of a wider consumer health challenge rather than a standalone category. (More)

DEAL OF THE WEEK

Lilly’s $2.9B Bet on the Next Immunology Platform

Eli Lilly agreed to acquire Merida Biosciences for up to $2.875B in cash, giving the pharma giant a new precision antibody-degradation platform as it continues expanding beyond its blockbuster obesity franchise.

The centerpiece is MER511, Merida’s lead program for Graves’ disease. For Merida’s backers—including Third Rock Ventures, Bain Capital Life Sciences, BVF Partners, GV and Perceptive Advisors—the deal provides a potentially sizable exit after the biotech raised roughly $154M.

The transaction also fits a broader Big Pharma playbook: rather than relying solely on internal R&D, strategics are using M&A to acquire promising platforms and pipelines earlier in their development.

The healthcare PE takeaway: Merida shows that differentiated science can still command multibillion-dollar strategic interest. For healthcare investors, the opportunity isn’t limited to approved drugs—the platforms capable of producing the next generation of therapies can be just as valuable.

Read more

DEAL TRACKER

~€3B | Astorg & Montagu → Nemera (Potential Sale)
Astorg and Montagu are exploring a sale of Nemera at a valuation of around €3B, potentially monetizing a healthcare picks-and-shovels play tied directly to booming GLP-1 drug delivery demand. Read more

~$1.53B | Roche → Simcere Zaiming’s SIM0660
Roche secured global rights to SIM0660 in a deal worth up to $1.53B plus royalties, extending Big Pharma’s growing appetite for China-origin biotech innovation. Read more

Up to $1.5B | AstraZeneca → Dizal’s Zegfrovy Rights
AstraZeneca completed its global licensing deal for Zegfrovy, paying $600M upfront with up to $900M in milestones for the approved oncology therapy ahead of its planned U.S. launch. Read more

~$1B | H.I.G. Capital → Rising Pharmaceuticals (Potential Sale)
H.I.G. Capital is reportedly exploring a sale of Rising Pharmaceuticals that could value the drugmaker at around $1B, adding another potential sponsor-backed healthcare exit to the pipeline. Read more

REGIONAL FOCUS

China’s Healthcare PE Reawakens

After several subdued years, Greater China’s healthcare private equity market is showing signs of a meaningful rebound. According to Bain, estimated buyout deal count more than doubled in 2025, from 19 to 43 deals, while disclosed deal value jumped from roughly $1.0B to $2.8B.

The recovery is notable because it reverses a steep contraction from the 2021 peak. Yet activity remains well below those highs, suggesting investors are returning selectively rather than indiscriminately. Bain points to renewed momentum across biopharma and medtech, as sponsors revisit a market that had been constrained by geopolitical uncertainty, regulatory shifts, and a difficult exit environment.

The bottom line: China’s healthcare PE market is reopening, but this is not 2021 redux. For investors, the opportunity may lie in entering during the recovery—particularly in innovative healthcare assets—before competition and valuations fully normalize.

Read more

INTERESTING ARTICLES